Peter Neumann
@peterneumann11.bsky.social
Excited to announce that David Strutton, Ph.D., a distinguished leader in healthcare policy, biopharmaceuticals, #vaccines, and #healtheconomics is joining Tufts-CEVR as a Senior Fellow.
Announcement here: cevr.tuftsmedicalcenter.org/news/david-s... @tuftscevr.bsky.social
Announcement here: cevr.tuftsmedicalcenter.org/news/david-s... @tuftscevr.bsky.social
July 29, 2025 at 2:41 PM
Excited to announce that David Strutton, Ph.D., a distinguished leader in healthcare policy, biopharmaceuticals, #vaccines, and #healtheconomics is joining Tufts-CEVR as a Senior Fellow.
Announcement here: cevr.tuftsmedicalcenter.org/news/david-s... @tuftscevr.bsky.social
Announcement here: cevr.tuftsmedicalcenter.org/news/david-s... @tuftscevr.bsky.social
New Tufts-CEVR paper in the J of Alzheimer's Disease, led by Paige Lin, provides updated health utility estimates for persons with AD and their caregivers across disease stages and settings.
journals.sagepub.com/doi/10.1177/... @tuftscevr.bsky.social @pattysynnott.bsky.social #Alzheimers
journals.sagepub.com/doi/10.1177/... @tuftscevr.bsky.social @pattysynnott.bsky.social #Alzheimers
June 20, 2025 at 3:47 PM
New Tufts-CEVR paper in the J of Alzheimer's Disease, led by Paige Lin, provides updated health utility estimates for persons with AD and their caregivers across disease stages and settings.
journals.sagepub.com/doi/10.1177/... @tuftscevr.bsky.social @pattysynnott.bsky.social #Alzheimers
journals.sagepub.com/doi/10.1177/... @tuftscevr.bsky.social @pattysynnott.bsky.social #Alzheimers
With @tuftscevr.bsky.social colleagues #ISPORAnnual in Montreal.
May 14, 2025 at 6:18 PM
With @tuftscevr.bsky.social colleagues #ISPORAnnual in Montreal.
Thanks to all my wonderful Tufts-CEVR colleagues for putting on another great annual meeting! Proud to work with you!
@dano-hta.bsky.social @brianreid.bsky.social @tuftscevr.bsky.social @mollytoba.bsky.social
@dano-hta.bsky.social @brianreid.bsky.social @tuftscevr.bsky.social @mollytoba.bsky.social
April 19, 2025 at 3:10 PM
Thanks to all my wonderful Tufts-CEVR colleagues for putting on another great annual meeting! Proud to work with you!
@dano-hta.bsky.social @brianreid.bsky.social @tuftscevr.bsky.social @mollytoba.bsky.social
@dano-hta.bsky.social @brianreid.bsky.social @tuftscevr.bsky.social @mollytoba.bsky.social
New study by my @tuftscevr.bsky.social colleague, Yolanda Zhu and colleagues.
The #IRA #Medicare Part D benefit redesign may significantly lower OOP drug spending for beneficiaries with #dementia and comorbidities.
tinyurl.com/5n8uxam3 #IRA #drugs
The #IRA #Medicare Part D benefit redesign may significantly lower OOP drug spending for beneficiaries with #dementia and comorbidities.
tinyurl.com/5n8uxam3 #IRA #drugs
March 4, 2025 at 8:02 PM
New study by my @tuftscevr.bsky.social colleague, Yolanda Zhu and colleagues.
The #IRA #Medicare Part D benefit redesign may significantly lower OOP drug spending for beneficiaries with #dementia and comorbidities.
tinyurl.com/5n8uxam3 #IRA #drugs
The #IRA #Medicare Part D benefit redesign may significantly lower OOP drug spending for beneficiaries with #dementia and comorbidities.
tinyurl.com/5n8uxam3 #IRA #drugs
Good piece by @araymakers.bsky.social et al. using the Tufts CEA Registry:
"Concerns over CEAs identifying subgroups in their analyses do not appear to be justified & does not warrant precluding the use of #QALYs for decision-making or price negotiation for drugs."
@tuftscevr.bsky.social
"Concerns over CEAs identifying subgroups in their analyses do not appear to be justified & does not warrant precluding the use of #QALYs for decision-making or price negotiation for drugs."
@tuftscevr.bsky.social
February 7, 2025 at 5:30 PM
Good piece by @araymakers.bsky.social et al. using the Tufts CEA Registry:
"Concerns over CEAs identifying subgroups in their analyses do not appear to be justified & does not warrant precluding the use of #QALYs for decision-making or price negotiation for drugs."
@tuftscevr.bsky.social
"Concerns over CEAs identifying subgroups in their analyses do not appear to be justified & does not warrant precluding the use of #QALYs for decision-making or price negotiation for drugs."
@tuftscevr.bsky.social
The outlook for US payer coverage of specialty drugs in 2005.
Register here for our webinar, Dec 4, 3-3:30 ET:
tinyurl.com/2pndy8v8
Register here for our webinar, Dec 4, 3-3:30 ET:
tinyurl.com/2pndy8v8
December 2, 2024 at 1:22 PM
The outlook for US payer coverage of specialty drugs in 2005.
Register here for our webinar, Dec 4, 3-3:30 ET:
tinyurl.com/2pndy8v8
Register here for our webinar, Dec 4, 3-3:30 ET:
tinyurl.com/2pndy8v8
Join us, Dec 4, 3-3:30 ET, as Tufts-CEVR's James Chambers discusses the outlook for US payer coverage of specialty drugs in 2025.
Register here: lnkd.in/g_GuE7bh.
Register here: lnkd.in/g_GuE7bh.
November 22, 2024 at 3:15 PM
Join us, Dec 4, 3-3:30 ET, as Tufts-CEVR's James Chambers discusses the outlook for US payer coverage of specialty drugs in 2025.
Register here: lnkd.in/g_GuE7bh.
Register here: lnkd.in/g_GuE7bh.
Just back from #ISPOREurope in Barcelona, where I discussed dynamic pricing in economic evaluation with @dano-hta.bsky.social Mark Sculpher & Beth Woods.
(Also did some sightseeing with Sean Tunis.)
(Also did some sightseeing with Sean Tunis.)
November 22, 2024 at 2:27 PM
Just back from #ISPOREurope in Barcelona, where I discussed dynamic pricing in economic evaluation with @dano-hta.bsky.social Mark Sculpher & Beth Woods.
(Also did some sightseeing with Sean Tunis.)
(Also did some sightseeing with Sean Tunis.)
The final agenda for the 10/26 symposium in Boston, "Celebrating Cost-Effectiveness Analysis," is now available.
Register in person or online:
tinyurl.com/2ab38f9p
Register in person or online:
tinyurl.com/2ab38f9p
October 17, 2024 at 7:02 PM
The final agenda for the 10/26 symposium in Boston, "Celebrating Cost-Effectiveness Analysis," is now available.
Register in person or online:
tinyurl.com/2ab38f9p
Register in person or online:
tinyurl.com/2ab38f9p